Success Metrics

Clinical Success Rate

100.0%

Based on 7 completed trials

Completion Rate

100%(7/7)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_3

57%

Ph phase_2

43%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 2Efficacy & side effects

3(42.9%)

Phase 3Large-scale testing

4(57.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 23 (42.9%)

Phase 34 (57.1%)

Trials by Status

completed7100%

Recent Activity

0 active trials

Showing 5 of 7

completedphase_2

Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

NCT04771780

completedphase_3

Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis

NCT04766385

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT03864445Phase 2

Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients

Completed

NCT03831607Phase 2

A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD

Completed

NCT03864458Phase 2

Dose-finding Study of KHK7791 in Hyperphosphatemia Patients

Completed

NCT04771780Phase 3

Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Completed

NCT04766385Phase 3

Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis

Completed

NCT04766398Phase 3

Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Completed

NCT04767581Phase 3

Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7